The bodies will assemble an international committee to guide future research and have planned a summit this fall for experts to discuss the implications of the technology.
Commercial software packages with a suite of additional features offer an alternative to academic guide RNA design tools for CRISPR/Cas9 genome editing.
High-throughput, systematic screens found 25 protein domains essential to AML, including six that are already drug targets in clinical trials.
The North Carolina-based firm plans to use the money to continue development of its Arcus genome editing platform.
The scientists will try to develop a platform that can find and edit genes responsible for key traits such as plant yield and disease resistance.
In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.
Adam Rutherford discusses genetic genealogy at the Guardian.
Portions of the US 21st Century Cures Act are raising some safety concerns.
David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.